Palvella Therapeutics (PVLA) COO Goin Sells $537K of Stock
Key Points
- Chief Operating Officer Kathleen Goin sold 4,313 shares of Palvella Therapeutics on October 21, 2026, at an average price of $124.58.
- The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, leaving the executive with zero direct shares.
- The biotechnology company reported an EPS of -$4.85 for the trailing twelve months and prepares to release its next financial update on November 11, 2026.
Since the trade, $PVLA is down 1.2% to date (from the $126.58 close on Oct 21, 2026).
Get Palvella Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $PVLA.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Palvella Therapeutics, Inc. alert may contain errors. Disclosures
Palvella Therapeutics, Inc. Chief Operating Officer Kathleen Goin sold 4,313 shares of the company on October 21, 2026. According to a Form 4 filed with the Securities and Exchange Commission, the shares were sold at an average price of $124.58 for a total value of about $537,307.50. The transaction was carried out under a pre-arranged trading plan.
PVLA
Palvella Therapeutics, Inc.
Inside Kathleen Goin's PVLA Trade
The planned sale covered 4,313 shares held directly by the chief operating officer. Following the execution of this transaction, the executive holds zero shares of the biotechnology firm, marking a 100.0% change in direct holdings. On the day of the trade, Palvella Therapeutics stock closed at $126.58.
Other Institutional Activity in Palvella Therapeutics
Other large funds have also adjusted their positions in the firm recently. Jennison Associates LLC grew its holdings by 319,993 shares, ending with 960,619 shares worth about $120,173,435. At the same time, Montanova Capital LLC trimmed its stake by 18,110 shares to hold 1,135,406 shares valued at roughly $142,039,288. Frazier Life Sciences Management, L.P. kept its holdings steady at 882,400 shares worth about $110,388,238. First Light Asset Management, LLC reduced its position by 208,913 shares to finish with 771,901 shares valued at approximately $96,564,813, and BVF Inc. cut its stake by 288,201 shares, leaving it with 672,789 shares worth about $84,165,902.
Palvella Therapeutics, Inc. Stock Down 1.2%
The company's shares recently traded around $125.10 as of October 23, 2026, sitting below the 50-day moving average of $143.06 and slightly under the 200-day moving average of $125.78. The stock has traded between a 52-week low of $68.96 and a 52-week high of $161.38.
Recent Earnings
Palvella Therapeutics reported a trailing-twelve-month net loss with an earnings per share of -$4.85. The clinical-stage biopharmaceutical firm is scheduled to deliver its next financial update on November 11, 2026.
Insider Buying and Selling at Palvella Therapeutics, Inc.
Director George M. Jenkins sold 13,152 shares on October 12, 2026, followed by sales of 7,174 shares on October 13, 2026, and another 7,174 shares on October 14, 2026. Earlier in the year, CFO and Treasurer Matthew Korenberg disposed of 1,000 shares on June 12, 2026.
Analysts Set New Price Targets
Chardan Capital maintains a buy rating on the stock with a $240.00 price target, while HC Wainwright & Co. maintains a buy rating with a target of $246.00 following an adjustment from $270.00. William Blair initiated coverage on the stock with an outperform rating on October 16, 2026. Overall, the company holds a consensus strong buy rating with a mean price target of $231.25 across 16 analyst opinions.
About Palvella Therapeutics
Palvella Therapeutics, Inc. is a Wayne, Pennsylvania-based biopharmaceutical firm focused on developing treatments for rare and serious genetic skin conditions. Its pipeline includes product candidates targeting microcystic lymphatic malformations and cutaneous venous malformations, positioning the clinical-stage enterprise around specialty dermatological care.
Bottom Line
Investors are keeping an eye on upcoming operational milestones and the next earnings report scheduled for November 11, 2026. Insider transactions like this planned sale provide a look at executive portfolio management without signaling an operational shift.
Related Filing Alerts
Source: Kathleen Goin's Form 4 filing on $PVLA (Oct 21, 2026). Written by software, not financial advice. How we make alerts